A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint

Inclusion Criteria:

Health Care Provider (HCP) Definitions

• Primary care physician (PCPs): physicians such as family medicine practitioners andinternists who do not specialize in neurological care.

• Secondary care physicians (SCPs): physicians such as geriatricians or neurologistswho see patients for specific reasons.

• Tertiary care physicians (TCPs): specialty neurologists who focus on certainneurological conditions.

HCP Participant Selection Criteria

• HCP inclusion criterion for each category of HCP is as follows:

• Group 1: PCPs who routinely evaluate and manage patients over the age of 50 ina family practice or internist setting.

• Group 2: SCPs and TCPs with experience diagnosing and treating patients withcognitive impairment and dementia.

Additional inclusion criteria applying to HCPs in the interventional group:

• Must be willing to review educational materials provided by the study sponsor,before enrolling patients.

Patient Participant Criteria

• Participants in the interventional group are eligible to be included in the studyonly if all the following criteria apply:

• Are capable of giving, and have given, signed informed consent.

• Have venous access sufficient to allow the protocol-required blood sampling.

• Are reliable, willing, and able to make themselves available for the durationof the study and are willing to follow study procedures.

Disease-specific Characteristics

• Present to the HCP with 1 or more subjective cognitive impairment complaints (SCIC)in the 4 weeks prior to identification: for example, worsening of memory, misplacingitems, difficulty concentrating, or new challenges with problem solving.

Patient Participant Exclusion Criteria:

• In the 18 months prior to identification have prior or associated HCP-orderedreferral or prior prescription of drug therapies, for the SCIC

• Participants with previous amyloid- or tau-specific tests, defined as

• Amyloid position emission tomography (PET)

• Tau PET

• Cerebral spinal fluid (CSF) tests for amyloid beta (Aβ) and/or tau biomarkers,or

• Blood tests for Aβ and/or tau biomarkers

• Has a current serious or unstable illness that in the enrolling investigator'sopinion could interfere with completion of the study or have a life expectancy ofless than 1 year.

• Has a known brain lesion, pathology, or prior alternative diagnosis that couldexplain the participant's clinical presentation.